论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Yusransyah, Halimah E, Suwantika AA
Received 10 February 2020
Accepted for publication 12 June 2020
Published 6 July 2020 Volume 2020:14 Pages 1103—1109
DOI https://doi.org/10.2147/PPA.S249085
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Johnny Chen
Introduction: The
prevalence of hypertension in Indonesia is increasing, not least in some
peripheral areas, including in Pandeglang District, Banten Province. The
government of Indonesia, through the Social Health Insurance Administration
Body (BPJS Kesehatan) has launched a chronic disease management program
(Prolanis) to achieve more optimal results in treating patients with chronic
diseases, including hypertension.
Objective: This
study aimed to measure the quality of life of Prolanis hypertension patients at
the primary healthcare centers (PHCs) using EuroQol-5 Dimensions-5 Levels
(EQ-5D-5L) instrument and taking pharmacists’ counseling intervention into
account. This study was conducted in 96 Prolanis patients, consisting of 48
patients from 8 PHCs who did not receive pharmacists’ counseling intervention
(control group) and 48 other patients from 8 different PHCs who received 4
times intervention (intervention group). This study was conducted in a period
of 3 months (June–August 2019) in 16 sub-districts of Pandeglang District.
Methods: An
experimental study design was applied by considering a purposive sampling
method. Patients’ quality of life were measured by using EQ-5D-5L instrument
and its Indonesian value set. For data analysis, we applied the Kruskal–Wallis,
Mann–Whitney, Wilcoxon, and Binomial tests to investigate the differences of
patients’ quality of life in both groups of control and intervention.
Results and Conclusions: The results showed that the average utility
value of the intervention group experienced an improvement at each meeting (m1
= 51.25%; m2 = 66.25%; m3 = 84.17%; and m4 = 91.67%), while the control group
experienced a lower and more fluctuative improvement than the intervention
group (m1 = 65.42%; m2 = 70.42%; m3 = 80.42%; and m4 = 76.67%). The same
results also occurred in the average value of visual analogue scale (VAS).
There was a better improvement in the intervention group than in the control
group.
Clinical Trial Registration Number: 62/UN6.KEP/EC/2019.
Keywords: quality
of life, Prolanis, hypertension, primary healthcare center, BPJS Kesehatan,
EQ-5D-5L